Skip to main content

Peer Review reports

From: Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS / BRAF metastatic colorectal cancer: The FLEET study

Original Submission
19 Mar 2015 Submitted Original manuscript
Author responded Author comments
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
6 Oct 2015 Editorially accepted
14 Oct 2015 Article published 10.1186/s12885-015-1685-z

You can find further information about peer review here.

Back to article page